Risk of developing hypothyroidism with the use of tyrosine kinase inhibitors and immune checkpoint inhibitors-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Risk of developing hypothyroidism with the use of tyrosine kinase inhibitors and immune checkpoint inhibitors

Published:2022-12 Issue: Volume:81 Page:102265
ISSN:1877-7821
Container-title:Cancer Epidemiology
language:en
Short-container-title:Cancer Epidemiology

Author:

Lee Seung Eun,Kim Kyoung-Ah,Lee Hyunjung,Park Jinkyeong

Funder

Dongguk University

Korea Health Industry Development Institute

National Research Foundation of Korea

Publisher

Elsevier BV

Subject

Cancer Research,Oncology,Epidemiology

Reference35 articles.

1. Molecular profiling for precision cancer therapies;Malone;Genome Med.,2020

2. Immunotherapy and targeted therapy-the new roadmap in cancer treatment;Shahid;Ann. Transl. Med.,2019

3. Development of immunotherapy combination strategies in cancer;Yap;Cancer Disco,2021

4. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma;Finn;N. Engl. J. Med.,2020

5. Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma;Rini;N. Engl. J. Med.,2019

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Safety evaluation of lenvatinib treatment after atezolizumab plus bevacizumab therapy for patients with unresectable liver cancer: A comparison of lenvatinib as 1st‑ or 2nd‑line treatment;Oncology Letters;2024-05-17

2. The Combined Effect of Immune Checkpoint Inhibitors and Tyrosine Kinase Inhibitors on Thyroid Function;Clinical Thyroidology®;2024-04-01

3. The Combined Effect of Immune Checkpoint Inhibitors and Tyrosine Kinase Inhibitors on Thyroid Function;Thyroid®;2024-02-01

4. Thyroid dysfunction with atezolizumab plus bevacizumab after lenvatinib in hepatocellular carcinoma: A case series;SAGE Open Medical Case Reports;2023-01

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3